1. A malignant tumor vaccine composition for mucosal administration for use in the induction of cellular immunity, comprising: (i) a WT1 peptide and / or a modified WT1 peptide； and (ii) a first activator of the induction of cellular immunity selected from a TLR ligand, a cyclic dinucleotide, a helper peptide, an immunomodulating low molecular weight drug, a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP fatty acid inhibitor, an inhibitor of an omega 3 fatty acid acid inhibitor, an inhibitor , PPAR agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serot agonist onin receptor, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarinic receptor antagonist, muscarinic receptor agonist, adrenaline receptor antagonist, adrenaline receptor agonist, agonistin agonist receptor agonist, agonistin agonist agonist, agoniston agonist, agonistin an ADP receptor agonist, a leukotriene receptor antagonist, a leukotriene receptor agonist, a melatonin receptor agonist, and a somatostatin receptor agonist, a cannabinoid receptor agonist, a sphingosine 1-phosphate receptor agonist, a glutamate metabotropic receptor agonist, a phospholipase A2 inhibitor, a TGF-β production inhibitor, a Th2-cytokine inhibitor, and a combination of two or more types thereof. 2. The vaccine composition according to claim 1, where the composition is intended for use in treatment�1. Вакцинная композиция против злокачественной опухоли для мукозального введения для применения в индукции клеточного иммунитета, содержащая:(i) пептид WT1 и/или модифицированный пептид WT1； и(ii) первый активатор индукции клеточного иммунитета, выбранный из лиганда TLR, циклического динуклеотида, хелперного пептида, иммуномодулирующего низкомолекулярного лекарственного средства, ингибитора циклооксигеназы, антагониста рецептора простагландина, агониста рец
